TuisOGN • NYSE
add
Organon & Co
Vorige sluiting
$7,36
Dagwisseling
$7,14 - $7,39
Jaarwisseling
$6,18 - $17,23
Markkapitalisasie
1,85 mjd USD
Gemiddelde volume
6,09 m
P/V-verhouding
3,71
Dividend-opbrengs
1,12%
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,60 mjd | 1,26% |
Bedryfskoste | 499,00 m | -6,38% |
Netto inkomste | 160,00 m | -55,43% |
Netto winsgrens | 9,99 | -55,97% |
Wins per aandeel | 1,01 | 16,09% |
EBITDA | 462,00 m | 0,65% |
Effektiewe belastingkoers | 34,16% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 672,00 m | -11,93% |
Totale bates | 13,55 mjd | 6,27% |
Totale aanspreeklikheid | 12,65 mjd | 3,16% |
Totale ekwiteit | 906,00 m | — |
Uitstaande aandele | 259,98 m | — |
Prys om te bespreek | 2,11 | — |
Opbrengs op bates | 6,84% | — |
Opbrengs op kapitaal | 9,55% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 160,00 m | -55,43% |
Kontant van bedrywe | 264,00 m | 87,23% |
Kontant van beleggings | -115,00 m | -53,33% |
Kontant van finansiering | -76,00 m | 2,56% |
Netto kontantverandering | 73,00 m | 23,73% |
Beskikbare kontantvloei | 96,25 m | 231,90% |
Meer oor
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States. Wikipedia
Gestig
1923
Webwerf
Werknemers
10 000
